Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Up 17.6% in September

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) saw a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 450,000 shares, an increase of 17.6% from the August 31st total of 382,600 shares. Based on an average daily volume of 116,500 shares, the days-to-cover ratio is currently 3.9 days.

Wall Street Analyst Weigh In

MIST has been the topic of several recent analyst reports. Rodman & Renshaw began coverage on Milestone Pharmaceuticals in a research report on Thursday, August 22nd. They set a “buy” rating and a $9.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a report on Thursday, August 22nd.

Milestone Pharmaceuticals Stock Down 0.3 %

Milestone Pharmaceuticals stock traded down $0.01 during midday trading on Monday, hitting $1.53. 56,540 shares of the stock were exchanged, compared to its average volume of 209,769. The stock has a market capitalization of $81.22 million, a price-to-earnings ratio of -1.21 and a beta of 1.71. The company has a quick ratio of 19.13, a current ratio of 19.13 and a debt-to-equity ratio of 1.61. The business’s 50-day moving average price is $1.45 and its 200-day moving average price is $1.54. Milestone Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $3.52.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. On average, research analysts expect that Milestone Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. BNP Paribas Financial Markets raised its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 177.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,900 shares of the company’s stock after buying an additional 10,800 shares during the period. BNP Paribas Financial Markets’ holdings in Milestone Pharmaceuticals were worth $30,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.